Adaptive clinical trials: the promise and the caution.

REFERENCES 1. American Heart Association. Heart Disease and Stroke Statistics – 2010 Update. Circulation doi: 10.1161/CIRCULATIONAHA.109. 192667 [epub ahead of print on December 17, 2009] 2. Hunt SA, Abraham WT, Chin MH, et al: 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53:e1-e90, 2009 3. Packer M: How should physicians view heart failure? : The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol 71:3C-11C, 1993 4. Packer M: The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 20:248-254, 1992 5. Izzo JL Jr, Gradman AH: Mechanisms and management of hypertensive heart disease: From left ventricular hypertrophy to heart failure. Med Clin North Am 88:1257-1271, 2004 6. Doroshow JH: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43:460-472, 1983 7. Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 97:2869-2879, 2003 8. Pinder MC, Duan Z, Goodwin JS, et al: Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808-3815, 2007 9. Crone SA, Zhao YY, Fan L, et al: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8:459-465, 2002 10. Negro A, Brar BK, Lee KF: Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 59:1-12, 2004 11. Ewer MS, Lippman SM: Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. J Clin Oncol 23:2900-2902, 2005 12. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007 13. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 14. Escudier B, Bellmunt J, Négrier S, et al: Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28:2144-2150, 2010 15. Rini BI, Halabi S, Rosenberg JE, et al: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 28:2137-2143, 2010 16. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006 17. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, doubleblind phase III trial. Lancet 370:2103-2111, 2007 18. Cobleigh MA, Langmuir VK, Sledge GW, et al: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30:117-124, 2003 19. Miller KD, O’Neill A, Perez EA, et al: Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104). J Clin Oncol 26:11s, 2008 (suppl; abstr 520) 20. Choueiri TK, Mayer EL, Je Y, et al: Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 29:632-638, 2011 21. Xu X, Li J, Simons M, et al: Expression of vascular endothelial growth factor and its receptors is increased, but microvascular relaxation is impaired in patients after acute myocardial ischemia. J Thorac Cardiovasc Surg 121:735-742, 2001 22. Giordano FJ, Gerber HP, Williams SP, et al: A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A 98:5780-5785, 2001 23. Sano M, Minamino T, Toko H, et al: p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446:444-448, 2007 24. Izumiya Y, Shiojima I, Sato K, et al: Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 47:887-893, 2006 25. D’Adamo DR, Anderson SE, Albritton K, et al: Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 23:7135-7142, 2005 26. Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247, 2010 27. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005 28. Robert NJ, Dieras V, Glaspy J, et al: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 27:42s, 2009 (suppl; abstr 1005) 29. Brufsky A, Rivera RR, Hurvitz SA, et al: Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 28:119s, 2010 (suppl; abstr 1021) 30. Zannad F, Stough WG, Pitt B, et al: Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: The need for a consensus definition. Eur Heart J 29:413-421, 2008